Machine learning–based insights into circulating autoantibody dynamics and treatment outcomes in patients with NSCLC receiving immune checkpoint inhibitors
IntroductionImmune checkpoint inhibitors (ICIs) targeting the programmed death-1/ligand-1 (PD-1/PD-L1) axis have significantly improved treatment outcomes in non-small cell lung cancer (NSCLC); however, challenges remain owing to the limited durability…